ZBIO Stock Price | Zenas BioPharma, Inc. Common Stock P/E, Revenue, EPS, & Forecasts

Zenas BioPharma, Inc. Common Stock • ZBIO

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Zenas BioPharma, Inc. Common Stock

Ticker

ZBIO

Trading on

NASDAQ

ISIN

US98937L1052

Industry

Biotechnology

Sector

Healthcare

CEO

Leon Oliver Moulder Jr., M.B.A.

Headquarters

852 Winter Street, Waltham, MA, United States, 02451

Employees

130

Website

https://zenasbio.com

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Metrics

BasicAdvanced

Market cap

$461M

P/E ratio

EPS

-$11.89

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-174M

Ex dividend date

Price & volume

Market cap

$461M

Average daily volume

0.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

30.71

Price to book

1.47

Earnings

EPS

-$11.89

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-174M

Revenues (TTM)

$15M

Revenues per share (TTM)

$0.65

Technicals

Beta

52-week High

$26.25

52-week Low

$5.83

50-day moving average

$8.92

200-day moving average

$11.75

Short ratio

22.79

Short %

17.13%

Management effectiveness

ROE (TTM)

-115.47%

ROA (TTM)

-56.70%

Profit margin

0.00%

Gross profit margin

$-136M

Operating margin

-373.30%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

41.8M

Float

21M

Insiders %

21.20%

Institutions %

74.81%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$32.14

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$5.02

-$9.30

46.05%

Q3 • 24Beat

-$1.26

-$1.02

-23.56%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$5M

$-52.6M

-1,052.08%

Q4 • 24

$10M

$-33.6M

-335.73%

Q1 • 25

100.00%

-36.18%

-68.09%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$370M

$57.5M

15.54%

Q4 • 24

$334M

$49.4M

14.82%

Q1 • 25

-9.79%

-14.02%

-4.69%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-38.6M

$-3.7M

$1.9M

$-38.6M

Q4 • 24

$-37.1M

$-86.3M

$0.1M

$-37.1M

Q1 • 25

-3.90%

2,209.88%

-94.66%

-4.04%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Zenas BioPharma, Inc. Common Stock share?

Zenas BioPharma, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Zenas BioPharma, Inc. Common Stock have?

Zenas BioPharma, Inc. Common Stock currently has 41.8M shares.

Does Zenas BioPharma, Inc. Common Stock pay dividends?

No, Zenas BioPharma, Inc. Common Stock doesn't pay dividends.

What is Zenas BioPharma, Inc. Common Stock 52 week high?

Zenas BioPharma, Inc. Common Stock 52 week high is $26.25.

What is Zenas BioPharma, Inc. Common Stock 52 week low?

Zenas BioPharma, Inc. Common Stock 52 week low is $5.83.

What is the 200-day moving average of Zenas BioPharma, Inc. Common Stock?

Zenas BioPharma, Inc. Common Stock 200-day moving average is $11.75.

Who is Zenas BioPharma, Inc. Common Stock CEO?

The CEO of Zenas BioPharma, Inc. Common Stock is Leon Oliver Moulder Jr., M.B.A..

How many employees Zenas BioPharma, Inc. Common Stock has?

Zenas BioPharma, Inc. Common Stock has 130 employees.

What is the market cap of Zenas BioPharma, Inc. Common Stock?

The market cap of Zenas BioPharma, Inc. Common Stock is $461M.

What is the P/E of Zenas BioPharma, Inc. Common Stock?

The current P/E of Zenas BioPharma, Inc. Common Stock is null.

What is the EPS of Zenas BioPharma, Inc. Common Stock?

The EPS of Zenas BioPharma, Inc. Common Stock is -$11.89.

What is the PEG Ratio of Zenas BioPharma, Inc. Common Stock?

The PEG Ratio of Zenas BioPharma, Inc. Common Stock is null.

What do analysts say about Zenas BioPharma, Inc. Common Stock?

According to the analysts Zenas BioPharma, Inc. Common Stock is considered a buy.